Page 6 - CIRN-AR-2015-PRESS.indd
P. 6
CIRN NETWORKS
Canadian National Vaccine
Safety Network (CANVAS)
Formerly known as the National Ambulatory Network (NAN) under PCIRN,
the new Canadian Vaccine Safety Network (CANVAS) has been created to
assess vaccine safety immediately after implementation of annual infl uenza
vaccine campaigns. The methodology and infrastructure will be leveraged
for studies related to safety of other vaccines used in these cohorts,
evaluation of vaccine hesitancy, and vaccine eff ectiveness. The network is
comprised of sites in Vancouver, Calgary, Toronto, Ottawa, Quebec City,
Sherbrooke, and Halifax.
The Canadian National Vaccine Safety (CANVAS)
network is meant to quickly gather and analyze safety
data on thousands of vaccinated individuals to provide
safety information to public health authorities before
the core weeks of vaccine campaigns. Since 2009,
the network has been monitoring the annual infl uenza
campaign, collecting safety data each year on more than
30,000 people who have gotten their infl uenza vaccine.
In 2014, CANVAS developed a mobile app to facilitate
safety monitoring using smartphones. In addition, last
year the network monitored the safety of the recently
approved serogroup B vaccine that was used in mass
immunization campaigns in Quebec. In February of this
year, researchers quickly moved to use the CANVAS
to study vaccine safety during mass immunization
campaign following an institutional outbreak of
meningococcal B disease in Nova Scotia. The study is
ongoing with research results expected in early summer.
Seven Canadian hospitals enroll health care workers at
their annual infl uenza vaccine campaign to report any
adverse events following immunization in an online
survey. The main objective is to estimate in children
and adults receiving infl uenza vaccine the frequency of
adverse events of suffi cient severity to cause medical
consultation or prevent daily activities. CANVAS also
developed and pilot tested a smart-phone safety app for
vaccine safety reporting at one site.
Canadian Immunization Research Network (CIRN)
Canadian National Vaccine
Safety Network (CANVAS)
Formerly known as the National Ambulatory Network (NAN) under PCIRN,
the new Canadian Vaccine Safety Network (CANVAS) has been created to
assess vaccine safety immediately after implementation of annual infl uenza
vaccine campaigns. The methodology and infrastructure will be leveraged
for studies related to safety of other vaccines used in these cohorts,
evaluation of vaccine hesitancy, and vaccine eff ectiveness. The network is
comprised of sites in Vancouver, Calgary, Toronto, Ottawa, Quebec City,
Sherbrooke, and Halifax.
The Canadian National Vaccine Safety (CANVAS)
network is meant to quickly gather and analyze safety
data on thousands of vaccinated individuals to provide
safety information to public health authorities before
the core weeks of vaccine campaigns. Since 2009,
the network has been monitoring the annual infl uenza
campaign, collecting safety data each year on more than
30,000 people who have gotten their infl uenza vaccine.
In 2014, CANVAS developed a mobile app to facilitate
safety monitoring using smartphones. In addition, last
year the network monitored the safety of the recently
approved serogroup B vaccine that was used in mass
immunization campaigns in Quebec. In February of this
year, researchers quickly moved to use the CANVAS
to study vaccine safety during mass immunization
campaign following an institutional outbreak of
meningococcal B disease in Nova Scotia. The study is
ongoing with research results expected in early summer.
Seven Canadian hospitals enroll health care workers at
their annual infl uenza vaccine campaign to report any
adverse events following immunization in an online
survey. The main objective is to estimate in children
and adults receiving infl uenza vaccine the frequency of
adverse events of suffi cient severity to cause medical
consultation or prevent daily activities. CANVAS also
developed and pilot tested a smart-phone safety app for
vaccine safety reporting at one site.
Canadian Immunization Research Network (CIRN)
